India, July 10 -- Sanofi (SNY) announced that the U.S. FDA has approved subcutaneous Sarclisa Escena in combination with standard-of-care regimen for the treatment of multiple myeloma across all existing indications of its intravenous formulation.
In the intravenous formulation, Sarclisa is approved for the following indications:
-- in combination with bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant.-- in combination with pomalidomide and dexamethasone in adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.-- in combination with carfilzomib and dexamethasone for the...